V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Measles
Conditions
Measles, Mumps, Rubella, Varicella
Trial Timeline
Sep 26, 2002 → Jun 9, 2003
NCT ID
NCT00092430About V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks is a phase 3 stage product being developed by Merck for Measles. The current trial status is completed. This product is registered under clinical trial identifier NCT00092430. Target conditions include Measles, Mumps, Rubella.
What happened to similar drugs?
4 of 17 similar drugs in Measles were approved
Approved (4) Terminated (1) Active (12)
🔄Measles-Rubella vaccine (Live) I.P. (Freeze Dried) of M/s. Zydus Lifesciences Ltd + Yellow fever Vaccine (WHO prequalified)Zydus LifesciencesPhase 3
❌Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™) + M-M-R™ II and Varivax™MerckPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00092430 | Phase 3 | Completed |
Competing Products
20 competing products in Measles